-------------------------
OMB APPROVAL
-------------------------
OMB Number: 3235-0058
Expires: April 30, 2009
Estimated average burden
hours per response ...
2.50
-------------------------
SEC FILE NUMBER
000-26753
-------------------------
(Check One) UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
|_| Form 10-K Washington, D.C. 20549
|_| Form 20-F
|_| Form 11-K FORM 12b-25
|X| Form 10-Q
|_| Form 10-D NOTIFICATION OF LATE FILING
|_| Form N-SAR
|_| Form N-CSR
For Period Ended: October 31, 2007.
|_| Transition Report on Form 10-K
|_| Transition Report on Form 20-F
|_| Transition Report on Form 11-K
|_| Transition Report on Form 10-Q
|_| Transition Report on Form N-SAR
For the Transition Period Ended:
---------------------
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- --------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
Amazon Biotech, Inc.
- --------------------------------------------------------------------------------
Full Name of Registrant
ASYST CORP
- --------------------------------------------------------------------------------
Former Name if Applicable
43 West 33rd Street
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
New York, NY 10001
- --------------------------------------------------------------------------------
City, State and Zip Code
- --------------------------------------------------------------------------------
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
a) The reason described in reasonable detail in Part III of this form
could not be eliminated ( without unreasonable effort or expense.
b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
|X| day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filled on or before
the fifth calendar day following the prescribed due ( date: and
c) The accountant's statement or other exhibit is required by Rule
12b-25(c) has been attached ( if applicable.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
PART III - NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR,
N-CSR, or the transition report or portion thereof, could not be filed within
the prescribed time period.
(Attach Extra Sheets if Needed)
The Company could not complete the filing of its Quarterly Report on Form 10-QSB
for the quarter ended October 31, 2007 due to a delay in obtaining and compiling
information required to be included in the Company's Form 10-QSB, which delay
could not be eliminated by the Company without unreasonable effort and expense.
Such delay was primarily the result of completing the detailed financial
statements. The Company intends to file its Quarterly Report on Form 10-QSB as
soon as practicable after the completion of the review by its officers and
directors.
- --------------------------------------------------------------------------------
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Mechael Kanovsky (212) 695-3334
- ------------------------ ------------- -----------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If the
answer is no, identify report(s). Yes |X| No |_|
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or portion
thereof? Yes |_| No |X|
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
- --------------------------------------------------------------------------------
Amazon Biotech, Inc.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: December 10, 2007 By: /s/ Mechael Kanovsky
-------------------------
Mechael Kanovsky
Chief Executive Officer